Infliximab improves bone metabolism and bone mineral density in rheumatoid arthritis and ankylosing spondylitis: a prospective 2-year study

Clin Rheumatol. 2013 Mar;32(3):377-81. doi: 10.1007/s10067-012-2128-8. Epub 2012 Nov 24.

Authors

Gabriel Dischereit¹, Ingo H Tarner, Ulf Müller-Ladner, Uwe Lange

Affiliation

¹ Department of Internal Medicine and Rheumatology, Justus-Liebig-University Giessen, Benekestrasse 2-8, D-61231 Bad Nauheim, Germany.

PMID: 23179009
DOI: 10.1007/s10067-012-2128-8

No abstract available

Publication types

Controlled Clinical Trial

MeSH terms

Absorptiometry, Photon
Adult
Aged
Aged, 80 and over
Antibodies, Monoclonal / pharmacology*
Antibodies, Monoclonal / therapeutic use
Antirheumatic Agents / pharmacology*
Antirheumatic Agents / therapeutic use
Arthritis, Rheumatoid / drug therapy
Arthritis, Rheumatoid / metabolism*
Bone Density / drug effects*
Bone and Bones / drug effects
Bone and Bones / metabolism*
Female
Femur / metabolism
Humans
Infliximab
Longitudinal Studies
Lumbar Vertebrae / metabolism
Male
Middle Aged
Pain Measurement
Pilot Projects
Prospective Studies
Severity of Illness Index
Spondylitis, Ankylosing / drug therapy
Spondylitis, Ankylosing / metabolism*
Surveys and Questionnaires
Treatment Outcome
Tumor Necrosis Factor-alpha / antagonists & inhibitors*

Substances

Antibodies, Monoclonal
Antirheumatic Agents
Tumor Necrosis Factor-alpha
Infliximab